Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SOPHiA GENETICS (SOPH) Liabilities and Shareholders Equity (2020 - 2025)

Historic Liabilities and Shareholders Equity for SOPHiA GENETICS (SOPH) over the last 6 years, with Q3 2025 value amounting to $163.5 million.

  • SOPHiA GENETICS's Liabilities and Shareholders Equity fell 796.7% to $163.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $643.1 million, marking a year-over-year decrease of 1369.07%. This contributed to the annual value of $155.3 million for FY2024, which is 2466.43% down from last year.
  • Latest data reveals that SOPHiA GENETICS reported Liabilities and Shareholders Equity of $163.5 million as of Q3 2025, which was down 796.7% from $177.6 million recorded in Q2 2025.
  • In the past 5 years, SOPHiA GENETICS's Liabilities and Shareholders Equity registered a high of $334.9 million during Q3 2021, and its lowest value of $104.0 million during Q2 2021.
  • Its 5-year average for Liabilities and Shareholders Equity is $215.4 million, with a median of $206.0 million in 2023.
  • Within the past 5 years, the most significant YoY rise in SOPHiA GENETICS's Liabilities and Shareholders Equity was 16645.46% (2022), while the steepest drop was 2517.99% (2022).
  • SOPHiA GENETICS's Liabilities and Shareholders Equity (Quarter) stood at $320.2 million in 2021, then decreased by 23.84% to $243.8 million in 2022, then decreased by 15.45% to $206.2 million in 2023, then fell by 24.66% to $155.3 million in 2024, then rose by 5.25% to $163.5 million in 2025.
  • Its Liabilities and Shareholders Equity was $163.5 million in Q3 2025, compared to $177.6 million in Q2 2025 and $146.7 million in Q1 2025.